First Time Loading...

United Therapeutics Corp
NASDAQ:UTHR

Watchlist Manager
United Therapeutics Corp Logo
United Therapeutics Corp
NASDAQ:UTHR
Watchlist
Price: 235.08 USD 1.07% Market Closed
Updated: Apr 16, 2024

Intrinsic Value

United Therapeutics Corp. operates as a biotechnology company engages in the development and commercialization of products for patients with chronic and life-threatening diseases. [ Read More ]

The intrinsic value of one UTHR stock under the Base Case scenario is 291.87 USD. Compared to the current market price of 235.08 USD, United Therapeutics Corp is Undervalued by 19%.

Key Points:
UTHR Intrinsic Value
Base Case
291.87 USD
Undervaluation 19%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
United Therapeutics Corp

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling UTHR stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
United Therapeutics Corp

Provide an overview of the primary business activities
of United Therapeutics Corp.

What unique competitive advantages
does United Therapeutics Corp hold over its rivals?

What risks and challenges
does United Therapeutics Corp face in the near future?

Has there been any significant insider trading activity
in United Therapeutics Corp recently?

Summarize the latest earnings call
of United Therapeutics Corp.

What significant events have occurred
in United Therapeutics Corp over the past months?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for United Therapeutics Corp.

Provide P/S
for United Therapeutics Corp.

Provide P/E
for United Therapeutics Corp.

Provide P/OCF
for United Therapeutics Corp.

Provide P/FCFE
for United Therapeutics Corp.

Provide P/B
for United Therapeutics Corp.

Provide EV/S
for United Therapeutics Corp.

Provide EV/GP
for United Therapeutics Corp.

Provide EV/EBITDA
for United Therapeutics Corp.

Provide EV/EBIT
for United Therapeutics Corp.

Provide EV/OCF
for United Therapeutics Corp.

Provide EV/FCFF
for United Therapeutics Corp.

Provide EV/IC
for United Therapeutics Corp.

Show me price targets
for United Therapeutics Corp made by professional analysts.

What are the Revenue projections
for United Therapeutics Corp?

How accurate were the past Revenue estimates
for United Therapeutics Corp?

What are the Net Income projections
for United Therapeutics Corp?

How accurate were the past Net Income estimates
for United Therapeutics Corp?

What are the EPS projections
for United Therapeutics Corp?

How accurate were the past EPS estimates
for United Therapeutics Corp?

What are the EBIT projections
for United Therapeutics Corp?

How accurate were the past EBIT estimates
for United Therapeutics Corp?

Compare the revenue forecasts
for United Therapeutics Corp with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of United Therapeutics Corp and its key competitors using the latest financial data.

Compare historical revenue growth rates
of United Therapeutics Corp against its competitors.

Analyze the profit margins
(gross, operating, and net) of United Therapeutics Corp compared to its peers.

Compare the P/E ratios
of United Therapeutics Corp against its peers.

Discuss the investment returns and shareholder value creation
comparing United Therapeutics Corp with its peers.

Analyze the financial leverage
of United Therapeutics Corp compared to its main competitors.

Show all profitability ratios
for United Therapeutics Corp.

Provide ROE
for United Therapeutics Corp.

Provide ROA
for United Therapeutics Corp.

Provide ROIC
for United Therapeutics Corp.

Provide ROCE
for United Therapeutics Corp.

Provide Gross Margin
for United Therapeutics Corp.

Provide Operating Margin
for United Therapeutics Corp.

Provide Net Margin
for United Therapeutics Corp.

Provide FCF Margin
for United Therapeutics Corp.

Show all solvency ratios
for United Therapeutics Corp.

Provide D/E Ratio
for United Therapeutics Corp.

Provide D/A Ratio
for United Therapeutics Corp.

Provide Interest Coverage Ratio
for United Therapeutics Corp.

Provide Altman Z-Score Ratio
for United Therapeutics Corp.

Provide Quick Ratio
for United Therapeutics Corp.

Provide Current Ratio
for United Therapeutics Corp.

Provide Cash Ratio
for United Therapeutics Corp.

What is the historical Revenue growth
over the last 5 years for United Therapeutics Corp?

What is the historical Net Income growth
over the last 5 years for United Therapeutics Corp?

What is the current Free Cash Flow
of United Therapeutics Corp?

AI Assistant can make mistakes. Consider checking important information.
Financials

Balance Sheet Decomposition
United Therapeutics Corp

Current Assets 3.6B
Cash & Short-Term Investments 3B
Receivables 278.9m
Other Current Assets 278m
Non-Current Assets 3.6B
Long-Term Investments 1.9B
PP&E 1B
Intangibles 114.2m
Other Non-Current Assets 518.1m
Current Liabilities 804.4m
Accounts Payable 298m
Other Current Liabilities 506.4m
Non-Current Liabilities 377.8m
Long-Term Debt 300m
Other Non-Current Liabilities 77.8m
Efficiency

Earnings Waterfall
United Therapeutics Corp

Revenue
2.3B USD
Cost of Revenue
-257.5m USD
Gross Profit
2.1B USD
Operating Expenses
-881.5m USD
Operating Income
1.2B USD
Other Expenses
-203.7m USD
Net Income
984.8m USD

Free Cash Flow Analysis
United Therapeutics Corp

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

UTHR Profitability Score
Profitability Due Diligence

United Therapeutics Corp's profitability score is 74/100. The higher the profitability score, the more profitable the company is.

74/100
Profitability
Score

United Therapeutics Corp's profitability score is 74/100. The higher the profitability score, the more profitable the company is.

UTHR Solvency Score
Solvency Due Diligence

United Therapeutics Corp's solvency score is 99/100. The higher the solvency score, the more solvent the company is.

High Interest Coverage
High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
99/100
Solvency
Score

United Therapeutics Corp's solvency score is 99/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

UTHR Price Targets Summary
United Therapeutics Corp

Wall Street analysts forecast UTHR stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for UTHR is 298.1 USD with a low forecast of 184.83 USD and a high forecast of 393.75 USD.

Lowest
Price Target
184.83 USD
21% Downside
Average
Price Target
298.1 USD
27% Upside
Highest
Price Target
393.75 USD
67% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

UTHR Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

UTHR Price
United Therapeutics Corp

1M 1M
+0%
6M 6M
+1%
1Y 1Y
+2%
3Y 3Y
+15%
5Y 5Y
+120%
10Y 10Y
+139%
Annual Price Range
235.08
52w Low
205.19
52w High
256.94
Price Metrics
Average Annual Return 31.03%
Standard Deviation of Annual Returns 38.44%
Max Drawdown -30%
Shares Statistics
Market Capitalization 11.1B USD
Shares Outstanding 47 058 500
Percentage of Shares Shorted 11.77%

UTHR Return Decomposition
Main factors of price return

What is price return decomposition?

UTHR News

Other Videos

Last Important Events
United Therapeutics Corp

Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.

All
Positive
Negative

Sentiment Analysis
United Therapeutics Corp

Today
Last 7 Days 7D
Last 30 Days 30D
Last 90 Days 90D

Company Profile

United Therapeutics Corp Logo
United Therapeutics Corp

Country

United States of America

Industry

Biotechnology

Market Cap

11.1B USD

Dividend Yield

0%

Description

United Therapeutics Corp. operates as a biotechnology company engages in the development and commercialization of products for patients with chronic and life-threatening diseases. The company is headquartered in Silver Spring, Maryland and currently employs 965 full-time employees. The firm markets and sells four commercial therapies in the United States to treat ulmonary arterial hypertension (PAH): Tyvaso (treprostinil) Inhalation Solution (Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso has also been approved to treat pulmonary hypertension associated with interstitial lung disease. The company also markets and sells an oncology product, Unituxin (dinutuximab) Injection (Unituxin), which is approved for the treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin (Remunity). The company also includes technologies designed supply of transplantable organs and tissues and improves outcomes for transplant recipients through regenerative medicine, three-dimensional (3-D) organ bioprinting, xenotransplantation and ex-vivo lung perfusion.

Contact

MARYLAND
Silver Spring
1040 Spring St
+13016089292.0
http://www.unither.com/

IPO

1999-06-17

Employees

965

Officers

Founder, Chairman & CEO
Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D.
President & COO
Mr. Michael I. Benkowitz
CFO & Treasurer
Mr. James C. Edgemond
Executive VP, General Counsel & Corporate Secretary
Mr. Paul A. Mahon J.D.
Head of Investor Relations
Mr. Dewey Steadman C.F.A.
Associate Vice President of Human Resources
Ms. Holly Hobson
Show More
Senior Vice President of Strategic Operations & Logistics
Kevin T. Gray
Executive VP of Technical Operations
Mr. Patrick Poisson
Senior Vice President of Product Development
Dr. Leigh Peterson
Senior VP & Chief Medical Officer
Mr. Gil Golden
Show Less

See Also

Discover More
What is the Intrinsic Value of one UTHR stock?

The intrinsic value of one UTHR stock under the Base Case scenario is 291.87 USD.

Is UTHR stock undervalued or overvalued?

Compared to the current market price of 235.08 USD, United Therapeutics Corp is Undervalued by 19%.